Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H13NO3.ClH |
Molecular Weight | 219.665 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNCC(O)C1=CC(O)=C(O)C=C1
InChI
InChIKey=ATADHKWKHYVBTJ-UHFFFAOYSA-N
InChI=1S/C9H13NO3.ClH/c1-10-5-9(13)6-2-3-7(11)8(12)4-6;/h2-4,9-13H,5H2,1H3;1H
Molecular Formula | C9H13NO3 |
Molecular Weight | 183.2044 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Racepinephrine or racemic epinephrine is a mixture of levo and dextro isomers of epinephrine act as a nonselective agonist at adrenergic receptors. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, shortness of breath. Inhaled racepinephrine became available in September 2012 as a nonprescription treatment for bronchospasm based on a 1986 US Food and Drug Administration rule. Besides, racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331074 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22220172 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseFor temporary relief of mild symptoms of intermittent asthma: wheezing, tightness of chest, shortness of breath |
|||
Palliative | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg single, oral Overdose |
unknown, 2 years |
Disc. AE: Hypertension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypertension (5.4%) Sources: Tachycardia (5.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | 5.4% Disc. AE |
50 mg single, oral Overdose |
unknown, 2 years |
Tachycardia | 5.4% Disc. AE |
50 mg single, oral Overdose |
unknown, 2 years |
PubMed
Title | Date | PubMed |
---|---|---|
Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors. | 1988 Dec |
|
Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. | 1993 Dec |
|
Carazolol: a potent, selective beta 3-adrenoceptor agonist. | 1995 Nov 30 |
|
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. | 1998 Apr 1 |
|
The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. | 2002 Apr |
|
Epinephrine as a mediator of pulmonary neutrophil sequestration. | 2002 Jul |
|
The efficacy of hemodynamic and T-wave criteria for detecting intravascular injection of epinephrine test dose in propofol-anesthetized adults. | 2002 Mar |
|
Exercise-induced changes in plasma composition increase erythrocyte Na+,K+-ATPase, but not Na+-K+-2Cl- cotransporter, activity to stimulate net and unidirectional K+ transport in humans. | 2003 Dec 15 |
|
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. | 2004 Feb |
|
Catecholamines potentiate the effect of thyroid hormone on intestinal absorption of glucose in the rat. | 2005 Jun |
|
[Experimental studies of rhizoma Astilbes chinensis on its effects in abirritation, blood activation, cough relieving and sputum elimination]. | 2006 Dec |
|
Strategies for enantioseparations of catecholamines and structurally related compounds by capillary zone electrophoresis using sulfated beta-cyclodextrins as chiral selectors. | 2006 Sep |
|
Extracellular signal-regulated kinase 1/2-mediated transcriptional regulation of G-protein-coupled receptor kinase 3 expression in neuronal cells. | 2007 Apr |
|
More PKA independent beta-adrenergic signalling via cAMP: is Rap1-mediated glucose uptake in vascular smooth cells physiologically important? | 2007 Jun |
|
Stereospecificity of mushroom tyrosinase immobilized on a chiral and a nonchiral support. | 2007 May 30 |
|
End-column chemiluminescence detection for pressurized capillary electrochromatographic analysis of norepinephrine and epinephrine. | 2007 Nov 2 |
|
Neuronal nitric oxide synthase gene inactivation reduces the expression of vasopressin in the hypothalamic paraventricular nucleus and of catecholamine biosynthetic enzymes in the adrenal gland of the mouse. | 2008 Jan |
|
Adrenaline-induced chronic ocular hypertension in adult rabbits. | 2009 Apr |
|
Characteristics and outcome of cardiopulmonary resuscitation in hospitalised African children. | 2009 Jan |
|
Enhanced voltammetric detection of epinephrine at a carbon nanotube/nafion composite electrode in the presence of ascorbic acid. | 2009 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/show/NCT00817466
Bronchiolitis: 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline (racepinephrine) 20mg/ml diluted in 2ml NaCl. Maximum 12 inhalations/24 hours
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:28:37 GMT 2025
by
admin
on
Mon Mar 31 18:28:37 GMT 2025
|
Record UNII |
336096P2WE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C319
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
||
|
CFR |
21 CFR 341.16
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m4944
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | Merck Index | ||
|
C73826
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
DTXSID9057717
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
206-346-0
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
329-63-5
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
CHEMBL1740
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
336096P2WE
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
336096P2WE
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
DBSALT001518
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
5924
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
100000127817
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
314610
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB33967
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY | |||
|
1598097
Created by
admin on Mon Mar 31 18:28:37 GMT 2025 , Edited by admin on Mon Mar 31 18:28:37 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
|
||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |